Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

Authors :: Ziemssen F
Heiduschka P
Schraermeyer U
Source :: Retina (Philadelphia, Pa.) [Retina] 2007 Oct; Vol. 27 (8), pp. 1154-6; author reply 1156-8.
Publication Year :: 2007

Subjects :: Antibodies, Monoclonal, Humanized
Choroidal Neovascularization etiology
Choroidal Neovascularization immunology
Humans
Macular Degeneration complications
Macular Degeneration immunology
Randomized Controlled Trials as Topic
Ranibizumab
Vascular Endothelial Growth Factor A immunology
Visual Acuity
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal therapeutic use
Choroidal Neovascularization drug therapy
Immunoglobulin Fab Fragments immunology
Macular Degeneration drug therapy

Full Text Access

Tools